United Kingdom

Manojna Maddipatla

UPDATE 2-VBI's shares plunge after hep B vaccine fails secondary goal in late-stage trial

17 Jun 2019

June 17 VBI Vaccines Inc said on Monday a late-stage study was unsuccessful in showing two doses of its hepatitis B vaccine were as effective as three doses of an older vaccine from GlaxoSmithKline, sending its shares plunging 66%.

Allergan's Vraylar wins FDA approval for bipolar depression

28 May 2019

Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

14 May 2019

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

Allergan CEO says company is urgently looking at all options to boost share price

07 May 2019

Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

Biogen dips as strategy post Alzheimer's setback fails to impress

24 Apr 2019

Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.

UnitedHealth sees minimal impact from rebate system overhaul

16 Apr 2019

UnitedHealth Group Inc said on Tuesday it expects minimal impact to its margins if the rebate system is overhauled but investors remained concerned about the impact of the Trump administration's proposal to end discounts from drugmakers.

Allergan depression treatment fails studies, shares slip

06 Mar 2019

Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.

Marriott revenue, FY forecast miss estimates on weak demand

01 Mar 2019

Marriott International Inc on Thursday missed Wall Street estimates for quarterly revenue and forecast a lower-than-expected full-year profit, blaming weak demand in North America, its largest market.

World News